Liraglutide biosimilar (University of Padova)

利拉鲁肽生物类似药（University of Padova）

Report date: 2025/03/07 17:33:45

Base Information

Drug NameLiraglutide biosimilar (University of Padova)
Drug Alias NameLiraglutidum利拉糖肽Liraglutida利拉鲁肽LATIN-T1D
ClassificationBiologics > Protein drugs > Recombinant polypeptideBiologics > Biosimilar
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsWolfram Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Padova
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Padova
Inactive CompaniesN/A
Active IndicationsWolfram Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG